Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma

ConclusionNivolumab is effective and tolerable in Japanese relapsed or refractory classical Hodgkin lymphoma patients. Continued monitoring may be necessary to detect late-onset pulmonary toxicities.Clinical trial registrationJapicCTI-142755 (Japan Pharmaceutical Information Center).
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research